Class I Recalls Break Record; FDA Begins Product-Specific Inquiries
This article was originally published in The Silver Sheet
Executive Summary
RECALLS OF MEDICAL DEVICES REACHED A RECORD LEVEL IN 2004, with 612 actions reported. A dramatic rise in Class I recalls has prompted FDA’s device center to look more closely at worrisome trends in certain product areas, including in vitro diagnostics. A new agency requirement for press releases on all Class I recalls should please consumers and members of Congress demanding greater openness from FDA, but a leading IVD industry spokeswoman questions the policy’s value to public health. Recent enforcement actions are a reminder that Class I recalls almost invariably lead to FDA scrutiny of a firm’s quality system
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.